Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Elusys anthrax antibody demonstrates safety
Anthim is being developed under the FDA animal rule, a regulatory process specifically designed for the development of medical countermeasures to bioterror threats. According to this rule, marketing
Anthim is being developed under the FDA animal rule, a regulatory process specifically designed for the development of medical countermeasures to bioterror threats. According to this rule, marketing
The unions claim that “Lipitor achieved its blockbuster clout in part through an ongoing fraudulent scheme that marketed the drug for off-label uses that are not approved by
The study is designed to test the ability of phenoxodiol to reverse the resistance that develops in most ovarian cancers to standard chemotherapy. The study was conducted at
Arena believes that the issues raised by the FDA may be resolvable using available data, but the company does not rule out the possibility that additional data may
The levels of the proteins, p24, a core protein in HIV cells, and IL-8, a pro-inflammatory cytokine, rise proportionately with increased HIV replication, making both of them standard
“Dara BioSciences’ R&D is the type of leading-edge pharmaceutical science for which our devices were developed,” said Marc Giroux, chairman and CEO of Kurve Technology. “We are thrilled
The collaboration will use Caprion’s CellCarta proteomics platform to support clinical biomarker discovery. Caprion will identify potential pharmacodynamic biomarkers in samples from certain undisclosed clinical and preclinical studies
The study will assess tumor response after four weeks of intra-tumoral injections of TNFerade plus concomitant radiation therapy in 29 patients with stage III or IV metastatic melanoma
FY2009 Outlook AMDL reaffirms that it is on track with its FY2009 projections and expects to meet its FY2009 financial guidance of estimated gross revenues of $64 –
The trial is evaluating PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with Millennium Pharmaceutical’s oncology drug Velcade. This trial is being sponsored by the National